Clinical Trial Update: Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nivolumab with or without varlilumab in relapsed or refractory aggressive B-cell lymphomas, including multiple DLBCL subtypes; results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Diffuse Large B-cell Lymphoma Activated B-cell Type
• Diffuse Large B-cell Lymphoma Germinal Center B-cell Type
• Diffuse Large B-cell Lymphoma of the Central Nervous System
• Ebv-positive Diffuse Large B-cell Lymphoma Not Otherwise Specified
• High-grade B-cell Lymphoma with Myc and Bcl2 and or Bcl6 Rearrangements
• Mediastinal Large B-cell Lymphoma
• Plasmablastic Lymphoma

Drugs mentioned

• OPDIVO (nivolumab)
• Varlilumab (varlilumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-10-16